Our News on Newswise

MD Anderson and UT Austin Create Unique Data-Driven Collaboration to Eliminate Cancer Using Novel Mathematical and Computational Approaches

The University of Texas MD Anderson Cancer Center and two institutions at The University of Texas at Austin – the Oden Institute for Computational Engineering and Sciences and the Texas Advanced Computing Center (TACC) – today announced a new...
24-Jun-2020 2:55 PM EDT Add to Favorites

Newswise: Gilchrist.jpg

Study shows sedentary behavior independently predicts cancer mortality

In the first study to look at objective measures of sedentary behavior and cancer mortality, researchers from The University of Texas MD Anderson Cancer Center found that greater inactivity was independently associated with a higher risk of dying...
18-Jun-2020 1:25 PM EDT Add to Favorites

Newswise: 173485_Goswami_G.jpg

Combination biomarker predicts response to immune checkpoint therapy in patients with advanced bladder cancer

A combination of two biomarkers was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors in patients with advanced bladder cancers.
15-Jun-2020 5:25 PM EDT Add to Favorites

MD Anderson and Philips collaborate to facilitate personalized oncology treatments and clinical trial matching based on genomic markers

MD Anderson and Philips today announced a collaboration to aid oncologists around the world to personalize therapy based on their patients' genomic profiles, with the aim of improving patient care.
16-Jun-2020 9:15 AM EDT Add to Favorites

Newswise: MDAnderson.jpg

MD Anderson and Rakuten Medical announce strategic alliance to advance Illuminox platform for cancer treatments

The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical’s proprietary IlluminoxTM...
4-Jun-2020 9:40 AM EDT Add to Favorites

Newswise: Le.jpg

Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of...
29-May-2020 10:30 AM EDT Add to Favorites

Newswise: Subbiah.jpg

Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers...
29-May-2020 10:20 AM EDT Add to Favorites

Newswise: Hong.jpg

Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck...
29-May-2020 10:05 AM EDT Add to Favorites


See All News

Our Experts on Newswise

Newswise: BenjaminSmith.jpg

Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT

Newswise: Liang_H_Bronto.jpg

Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT

Newswise: ZhiminLu.jpg

MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT

Newswise: Lee_M.jpg

Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT

Newswise: 204929_Chhatwal_Jjpg.jpg

MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

MD Anderson Energy Balance Expert Available for Obesity, Cancer Stories

30-Oct-2013 8:10 PM EDT

MD Anderson Obesity and Cancer Expert Researches Food Addiction

30-Oct-2013 8:00 PM EDT

See All Experts

Our YouTube Videos

About

About section not configured. Is this your member page? Login to edit, or contact member@newswise.com to configure this module.

Contacts

Clayton Boldt

crboldt@mdanderson.org

713-792-9518

Katrina Burton
Senior Communications Specialist

kburton@mdanderson.org

713-792-8034

Kelly Calagna

kccalgna@mdanderson.org

Meagan Raeke

meraeke@mdanderson.org

Allison Schaffer
Senior Communications Specialist

ASchaffer@mdanderson.org

713-745-1357

Twitter

close
0.75137